Stockreport
Argenx SE reports 9M results [Seeking Alpha]
US:NASDAQ Investor Relations: investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
PDF
Argenx SE reports 9M resultsArgenx SE (Pending:ARGX): 9M Comprehensive loss of €16.46MRevenue of €28.42B (+170.2% Y/Y)Press ReleaseNow read:MannKind Heat Check »
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ARGX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ARGX alerts
ARGX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting ARGENX SE ADS news events
Weekly update
A roundup of the hottest topics
ARGX
NEWS
NEWS
- argenx SE - (NASDAQ: ARGX) is now covered by analysts at Nomura. They set a "buy" rating and a $161.00 price target on the stock.[MarketBeat]
- argenx receives second preclinical milestone payment under its development agreement with AbbVie[GlobeNewswire]
- argenx SE - (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $114.00 price target on the stock, up previously from $93.00.[MarketBeat]
- argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris[GlobeNewswire]
- argenx SE - (NASDAQ: ARGX) had its price target raised by analysts at JMP Securities from $93.00 to $130.00. They now have a "positive" rating on the stock.[MarketBeat]
- More
ARGX
SEC Filings
SEC Filings
- 6/28/18 - Form 6-K
- 6/20/18 - Form 6-K
- 6/14/18 - Form 6-K
- ARGX's page on the SEC website
- More